Correction to stock exchange release: Siili Solutions Plc: Business review, 1 January – 31 March 2024
April 24, 2024 09:55 ET
|
Siili Solutions Oyj
Correction to stock exchange release: Siili Solutions Plc: Business review, 1 January – 31 March 2024 Siili Solutions Plc Stock exchange release 24 April 2024 at 16:55 This is a correction...
Verana Health Announces Launch of Qdata® Thyroid Eye Disease
April 24, 2024 09:00 ET
|
Verana Health, Inc.
SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), today...
Nova Klúbburinn hf. - Leiðrétting - Tilkynning um framkvæmd endurkaupaáætlunar
April 24, 2024 04:42 ET
|
Nova
Framkvæmd áætlunarinnar hefst í dag, miðvikudaginn 24. apríl. Léðrétt tilkynning er hér að neðan. Á aðalfundi Nova Klúbbsins hf. þann 21. mars 2024 var stjórn félagsins veitt heimild til að kaupa...
Nova Klúbburinn hf. - Tilkynning um framkvæmd endurkaupaáætlunar
April 24, 2024 04:30 ET
|
Nova
Á aðalfundi Nova Klúbbsins hf. þann 21. mars 2024 var stjórn félagsins veitt heimild til að kaupa allt að 10% af eigin bréfum fyrir félagsins hönd í því skyni að setja upp formlega endurkaupaáætlun...
Siili Solutions Plc: Business review, 1 January–31 March 2024
April 24, 2024 02:45 ET
|
Siili Solutions Oyj
Siili Solutions Plc: Business review, 1 January–31 March 2024 Siili’s result decreased as expected, good development within AI Siili Solutions Plc Stock Exchange Release 24 April 2024 at 9:45 am...
Síminn hf. - Afkoma fyrsta ársfjórðungs 2024
April 23, 2024 11:34 ET
|
Síminn hf.
Helstu niðurstöður úr rekstri á 1F 2024 Tekjur á fyrsta ársfjórðungi (1F) 2024 námu 6.575 m.kr. samanborið við 6.298 m.kr. á sama tímabili 2023 og jukust um 4,4%. Tekjur af kjarnaþjónustum...
Novartis erzielt im ersten Quartal ein zweistelliges Umsatzwachstum und steigert die Kerngewinnmarge; Prognose für das Geschäftsjahr 2024 erhöht
April 23, 2024 01:00 ET
|
Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KRDer Nettoumsatz wuchs im ersten Quartal um +11% (kWk1, +10% USD), das operative Kernergebnis verbesserte sich um +22% (kWk, +16% USD)Die wichtigsten...
Gróska ehf: Ársreikningur 2023
April 18, 2024 11:46 ET
|
Gróska ehf
Ársreikningur Grósku ehf. fyrir árið 2023 var samþykktur af stjórn og framkvæmdastjóra félagsins þann 18. apríl 2024. Ársreikning má finna hér í viðhengi eða á heimasíðu félagsins https://groska.is/...
Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
April 18, 2024 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...
Polycythemia Pipeline Insight 2024, Featuring Protagonist Therapeutics, Ionis Pharmaceuticals, Perseus Proteomics, Kartos Therapeutics, Imago BioSciences, Incyte, Italfarmaco, Lynk and Promedior
April 18, 2024 03:53 ET
|
Research and Markets
Dublin, April 18, 2024 (GLOBE NEWSWIRE) -- The "Polycythemia - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The report provides comprehensive insights...